About Us Contact Us Sitemap

Choroideremia Market, By Treatment Type (Gene Therapy, Surgical Intervention, Pharmacological Treatment, Symptomatic Treatment, Cell Therapy, and Drug Therapy), By Route of Administration, By Patient Demographics, By Disease Stage, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

Market Research Image
Report ID AV4990
Published Date March 2026
Pages 304
Industry Healthcare
Format PPT/PDF
Base Year 2025
Historical Data 2019-2024
Delivery Timeline 24 Hour

REPORT HIGHLIGHT

Choroideremia market size was valued at US$ 9,785.95 Million in 2025, expanding at a CAGR of 4.87% from 2026 to 2033.

Choroideremia is a rare inherited eye disorder that primarily affects males and leads to progressive vision loss. The condition typically begins with difficulty seeing in low-light conditions, gradually affecting peripheral vision, and eventually impacting central vision, which can result in blindness. According to data from the U.S. National Institutes of Health, choroideremia affects approximately 1 in 50,000 to 100,000 individuals and accounts for a small portion of blindness cases. The choroideremia market encompasses the development and commercialization of treatments for this rare disease, with a particular focus on emerging therapies such as gene therapy. Despite the limited patient population, the market is growing due to increased investment in research, the development of innovative treatment approaches, and the pressing need for therapies that can slow or halt vision loss over time.

Choroideremia Market- Market Dynamics

Growing Focus on the Development of Gene Therapies

A major driver of the choroideremia market is the growing focus on gene therapy development, supported by government initiatives and regulatory incentives. The National Institutes of Health (NIH) promotes gene therapy programs for rare diseases through funding and targeted initiatives, recognizing the limited treatment options available for such conditions. Since choroideremia results from a single-gene mutation, it is particularly suited for gene replacement therapies, and government-supported research has already advanced several candidates into clinical trials with promising patient outcomes. Companies such as Biogen Inc., Spark Therapeutics, and REGENXBIO Inc. are actively developing these treatments. Furthermore, the U.S. Food and Drug Administration (FDA) provides orphan drug and rare disease designations, accelerating development timelines and boosting research activity, thereby driving market growth.

Choroideremia Market- Segmentation Analysis:
The Global Choroideremia Market is segmented on the basis of Treatment Type, Route of Administration, Patient Demographics, Disease Stage, End User, and Region.

The market for choroideremia treatments is segmented by treatment type into gene therapy, surgical intervention, pharmacological treatment, symptomatic treatment, cell therapy, and drug therapy, with gene therapy emerging as the most critical segment. Unlike other approaches that only manage symptoms, gene therapy addresses the root cause of the disease by repairing the defective CHM gene responsible for vision loss. Choroideremia is an extremely rare disorder, affecting roughly 1 in 50,000 to 100,000 people globally, which has led governments to classify it as a rare disease and provide targeted support through orphan drug programs, dedicated research funding, and fast-track regulatory pathways. Gene therapy’s use of viral vectors, such as adeno-associated viruses (AAV), to deliver functional genes to retinal cells has already demonstrated maintained or improved vision in clinical trials, making it the primary focus of most funding, research, and regulatory attention. Globally, over 35 countries have implemented orphan drug frameworks or rare disease incentives, supporting the development and commercialization of advanced gene therapies, emphasizing the pivotal role of government in accelerating adoption of curative treatments.

When analyzed by route of administration, the market is divided into subretinal injection, intravitreal injection, oral route, and intravenous route, with subretinal injection playing a central role in gene therapy for choroideremia. This route delivers the therapeutic gene directly to the retinal cells affected by the disease, ensuring higher precision and concentration at the target site. Government-backed clinical studies confirm that subretinal administration is the preferred method in trials involving AAV-based therapies, targeting the retinal pigment epithelium and photoreceptors effectively. Despite being more invasive than alternatives like intravitreal injections, subretinal delivery offers improved treatment efficacy, suitability for one-time therapy, and targeted gene transfer, making it the most widely adopted route for choroideremia. Regulatory agencies across more than 20 countries actively fund and oversee clinical trials using subretinal delivery, reflecting government prioritization of safe and effective delivery methods in rare disease treatment development, further reinforcing its dominant role in the market.

Choroideremia Market- Geographical Insights

North America is expected to experience significant growth in the choroideremia market, driven by a strong research ecosystem and sustained government support for rare disease therapies. The National Institutes of Health (NIH) funds numerous gene therapy programs targeting inherited retinal diseases, supporting both early-stage and clinical research. Additionally, the U.S. Food and Drug Administration (FDA) offers orphan drug designations, which help accelerate the development of new treatments. Government-backed studies in the U.S. have already advanced gene therapies for choroideremia into human clinical trials, demonstrating measurable improvements in vision, with companies such as Spark Therapeutics and REGENXBIO Inc. leading development efforts. Europe is also emerging as a key market, supported by active clinical research and public healthcare initiatives. Government-funded trials in the United Kingdom, including support from the UK Department of Health, have facilitated early human studies of subretinal gene therapy, while structured rare disease policies continue to promote ongoing research and improve patient access.

Canada Choroideremia Market- Country Insights

Canada is a key market for choroideremia due to consistent government-supported research and a strong healthcare focus on rare eye diseases. According to data from organizations such as Fighting Blindness Canada, approximately 21,000 Canadians live with inherited retinal diseases, including choroideremia, representing a clearly defined patient population in need of long-term care and treatment. Government-linked clinical studies further indicate that over 68% of patients with these conditions are legally blind, highlighting a significant healthcare burden and the need for effective therapies. Canada also benefits from strong academic and clinical involvement, with institutions like the University of Alberta contributing to genetic research and the diagnosis of choroideremia. Gene-based research initiatives are supported through public healthcare programs and collaborations with global biotech companies. Overall, Canada’s structured healthcare system, ongoing research efforts, and well-defined patient base create a stable environment for the continued development and adoption of innovative treatments.

Choroideremia Market- Competitive Landscape:

The competitive landscape of the choroideremia market is primarily driven by biotechnology and pharmaceutical companies focusing on gene-based therapies, due to the limited number of approved treatments and ongoing clinical development. Key players include Biogen Inc., Spark Therapeutics, REGENXBIO Inc., MeiraGTx Holdings plc, and 4D Molecular Therapeutics, all developing AAV-based gene therapies targeting the underlying genetic cause of the disease. Government-supported clinical data indicate that multiple gene therapy trials for choroideremia have progressed through Phase I, II, and III stages across the U.S., UK, and other regions, demonstrating steady development activity. Public research funding from organizations such as the UK’s National Institute for Health and Care Research, among others, further supports clinical studies and infrastructure for these trials. The market remains research-driven, with companies prioritizing clinical trial advancement, regulatory approvals, and long-term treatment outcomes, as gene therapy continues to dominate development efforts.

Recent Developments:

  • October 2025: DelveInsight and other industry reports highlighted the expansion of clinical research and multi-modal approaches—including gene therapy, gene editing, RNA-based therapies, and optogenetics—progressing through preclinical and clinical stages for choroideremia. This trend indicates a diversification of therapeutic strategies, with multiple technologies being explored to target the disease from different angles, reflecting steady progress and broader future treatment potential.

  • June 2025: The Choroideremia Research Foundation awarded six new global research grants to accelerate vision science and therapeutic innovation, funding projects such as CRISPR-based gene editing and long-term gene therapy follow-up studies. These initiatives demonstrate continued scientific and financial support for advanced research approaches, focusing on improving long-term outcomes and expanding the range of potential therapies for choroideremia.

SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOROIDEREMIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • MeiraGTx Limited (U.K.)
  • REGENXBIO (U.S.)
  • GenSight Biologics (France)
  • Editas Medicine (U.S.)
  • Spark Therapeutics (U.S.)
  • Sangamo Therapeutics (U.S.)
  • CRISPR Therapeutics AG (Switzerland)
  • Nanoscope Therapeutics, Inc. (U.S.)
  • 4D Molecular Therapeutics (U.S.)
  • ProQR Therapeutics N.V. (Netherlands)
  • Horama SA (France)
  • Homology Medicines, Inc. (U.S.)
  • Beacon Therapeutics (U.S.)
  • Eyevensys (Switzerland)
  • Visgenx (U.S.)
  • Atsena Therapeutics Inc. (U.S.)
  • Coave Therapeutics (U.S.)
  • Neurophth Therapeutics (China)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Ocugen, Inc. (U.S.)

GLOBAL CHOROIDEREMIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

  • Gene Therapy
  • Surgical Intervention
  • Pharmacological Treatment
  • Symptomatic Treatment
  • Cell Therapy
  • Drug Therapy

GLOBAL CHOROIDEREMIA MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Subretinal Injection
  • Intravitreal Injection
  • Oral Route
  • Intravenous Route

GLOBAL CHOROIDEREMIA MARKET, BY PATIENT DEMOGRAPHICS- MARKET ANALYSIS, 2020 - 2033

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

GLOBAL CHOROIDEREMIA MARKET, BY DISEASE STAGE- MARKET ANALYSIS, 2020 - 2033

  • Early Stage
  • Mid Stage
  • Late Stage

GLOBAL CHOROIDEREMIA MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Specialty Ophthalmology Clinics
  • Ambulatory Surgical Centers
  • Research & Academic Institutes
  • Homecare Settings

GLOBAL CHOROIDEREMIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM

The Middle East and Africa

  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

TABLE OF CONTENT

1. Choroideremia Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Choroideremia Market Snippet by Treatment Type
2.1.2. Choroideremia Market Snippet by Route of Administration
2.1.3. Choroideremia Market Snippet by Patient Demographics
2.1.4. Choroideremia Market Snippet by Disease Stage
2.1.5. Choroideremia Market Snippet by End User
2.1.6. Choroideremia Market Snippet by Country
2.1.7. Choroideremia Market Snippet by Region
2.2. Competitive Insights
3. Choroideremia Key Market Trends
3.1. Choroideremia Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Choroideremia Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Choroideremia Market Opportunities
3.4. Choroideremia Market Future Trends
4. Choroideremia Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Choroideremia Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Choroideremia Market Landscape
6.1. Choroideremia Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Choroideremia Market – By Treatment Type
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
7.1.2. Gene Therapy
7.1.3. Surgical Intervention
7.1.4. Pharmacological Treatment
7.1.5. Symptomatic Treatment
7.1.6. Cell Therapy
7.1.7. Drug Therapy
8. Choroideremia Market – By Route of Administration
8.1. Overview
8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
8.1.2. Subretinal Injection
8.1.3. Intravitreal Injection
8.1.4. Oral Route
8.1.5. Intravenous Route
9. Choroideremia Market – By Patient Demographics
9.1. Overview
9.1.1. Segment Share Analysis, By Patient Demographics, 2025 & 2033 (%)
9.1.2. Pediatric Patients
9.1.3. Adult Patients
9.1.4. Geriatric Patients
10. Choroideremia Market – By Disease Stage
10.1. Overview
10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
10.1.2. Early Stage
10.1.3. Mid Stage
10.1.4. Late Stage
11. Choroideremia Market – By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
11.1.2. Hospitals
11.1.3. Specialty Ophthalmology Clinics
11.1.4. Ambulatory Surgical Centers
11.1.5. Research & Academic Institutes
11.1.6. Homecare Settings
12. Choroideremia Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
12.2. North America
12.2.1. Overview
12.2.2. Choroideremia Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.2.6. North America Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.2.7. North America Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Choroideremia Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Choroideremia Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Choroideremia Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Choroideremia Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
13. Key Vendor Analysis- Choroideremia Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. MeiraGTx Limited (U.K.)
13.2.2. REGENXBIO (U.S.)
13.2.3. GenSight Biologics (France)
13.2.4. Editas Medicine (U.S.)
13.2.5. Spark Therapeutics (U.S.)
13.2.6. Sangamo Therapeutics (U.S.)
13.2.7. CRISPR Therapeutics AG (Switzerland)
13.2.8. Nanoscope Therapeutics, Inc. (U.S.)
13.2.9. 4D Molecular Therapeutics (U.S.)
13.2.10. ProQR Therapeutics N.V. (Netherlands)
13.2.11. Horama SA (France)
13.2.12. Homology Medicines, Inc. (U.S.)
13.2.13. Beacon Therapeutics (U.S.)
13.2.14. Eyevensys (Switzerland)
13.2.15. Visgenx (U.S.)
13.2.16. Atsena Therapeutics Inc. (U.S.)
13.2.17. Coave Therapeutics (U.S.)
13.2.18. Neurophth Therapeutics (China)
13.2.19. Johnson & Johnson Services, Inc. (U.S.)
13.2.20. Ocugen, Inc. (U.S.)
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOROIDEREMIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • MeiraGTx Limited (U.K.)
  • REGENXBIO (U.S.)
  • GenSight Biologics (France)
  • Editas Medicine (U.S.)
  • Spark Therapeutics (U.S.)
  • Sangamo Therapeutics (U.S.)
  • CRISPR Therapeutics AG (Switzerland)
  • Nanoscope Therapeutics, Inc. (U.S.)
  • 4D Molecular Therapeutics (U.S.)
  • ProQR Therapeutics N.V. (Netherlands)
  • Horama SA (France)
  • Homology Medicines, Inc. (U.S.)
  • Beacon Therapeutics (U.S.)
  • Eyevensys (Switzerland)
  • Visgenx (U.S.)
  • Atsena Therapeutics Inc. (U.S.)
  • Coave Therapeutics (U.S.)
  • Neurophth Therapeutics (China)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Ocugen, Inc. (U.S.)

GLOBAL CHOROIDEREMIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

  • Gene Therapy
  • Surgical Intervention
  • Pharmacological Treatment
  • Symptomatic Treatment
  • Cell Therapy
  • Drug Therapy

GLOBAL CHOROIDEREMIA MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Subretinal Injection
  • Intravitreal Injection
  • Oral Route
  • Intravenous Route

GLOBAL CHOROIDEREMIA MARKET, BY PATIENT DEMOGRAPHICS- MARKET ANALYSIS, 2020 - 2033

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

GLOBAL CHOROIDEREMIA MARKET, BY DISEASE STAGE- MARKET ANALYSIS, 2020 - 2033

  • Early Stage
  • Mid Stage
  • Late Stage

GLOBAL CHOROIDEREMIA MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Specialty Ophthalmology Clinics
  • Ambulatory Surgical Centers
  • Research & Academic Institutes
  • Homecare Settings

GLOBAL CHOROIDEREMIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM

The Middle East and Africa

  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA
Request For Sample
Choose License Type
assit assit
Related Reports

Credibility and Certifications

Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

ISO Certification ISO 9001:2015
ESOMAR Individual ESOMAR Corporate
GDPR Compliance GDPR Compliance
D-U-N-S Registered D-U-N-S Registered
BBB Accreditation BBB Accreditation
MRS MRS
CONTACT INFORMATION

Email:

[email protected]

U.S. Office

11923 NE Sumner St STE 750924
Portland, Oregon, 97220, USA

Asia Pacific Office

4, Rohan Business Centre, Paud Road,
Kothrud, Pune Maharashtra, 411038, India

QUICK LINKS
RESOURCES
Secure Payment By
PayPal
Visa
MasterCard
American Express
Support Hours

We’re here to assist you around the clock, six days a week.

Monday – Friday: 10:00 AM to 6:00 PM

Saturday: 10:00 AM to 3:00 PM

Sunday: Closed

© Copyright 2026 Analystview Market Insights | All Rights Reserved